Income-seeking investors often compare RDIV and SCHD because both sit in the large-cap value and dividend segment of the U.S. equity market. Yet they are not direct substitutes. SCHD emphasizes dividend quality, stability, and long-term growth, while RDIV prioritizes raw dividend yield through a revenue-weighted framework. This ETF comparison matters now because the ongoing rotation between growth and value, shifting interest-rate expectations, and renewed demand for income have brought both funds into focus. When I reviewed the latest holdings data, I also checked this using Tickeron’s AI Screener to see how the two line up against peers. Understanding the structural differences between these strategies—rather than short-term price moves—is essential for any investor evaluating sector exposure and relative positioning in an income portfolio.
RDIV tracks the S&P 900 Dividend Revenue-Weighted Index, a rules-based benchmark that starts with the S&P 900, removes the highest-yielding 5% of names and the top 5% of payers within each sector, then selects the 60 highest-yielding stocks and weights them by total revenue. This produces a concentrated, non-diversified portfolio of roughly 60 to 61 holdings that is reconstituted and rebalanced quarterly.
The fund's sector allocation skews toward cyclical and defensive income names, led by consumer staples, financials, communication services, energy, and real estate, with a modest weight in healthcare and little to no technology exposure. Representative top holdings include Comcast, Prudential Financial, PepsiCo, Ford Motor, Bristol-Myers Squibb, AT&T, ONEOK, and Chevron. The net expense ratio is 0.39%, and the fund's revenue-weighting approach gives it a large-cap value orientation with a forward P/E ratio well below the broad market. Its elevated yield comes with meaningful single-stock and cyclical concentration risk.
SCHD tracks the Dow Jones U.S. Dividend 100 Index, which selects roughly 100 U.S. companies that have paid dividends for at least 10 consecutive years and screens them on metrics such as cash flow to total debt, return on equity, dividend yield, and five-year dividend growth. The result is a quality-oriented, diversified portfolio of about 100 to 104 holdings that is reviewed quarterly and reconstituted annually.
Sector exposure is anchored in energy, consumer staples, healthcare, and industrials, with additional weight in financials, information technology, and consumer discretionary. Top holdings have included Merck, Abbott Laboratories, Amgen, Coca-Cola, Home Depot, Verizon Communications, ConocoPhillips, Chevron, UnitedHealth Group, and Procter & Gamble. The fund charges a 0.06% expense ratio and carries a lower beta than RDIV, reflecting a defensive, large-cap value profile built around financially durable dividend payers rather than the highest-yielding names.
Both funds operate at the intersection of income investing and the value trade, and both are sensitive to the macro backdrop. Rising bond yields can pressure dividend equities by offering competing risk-free income, while falling yields tend to revive demand for yield-bearing stocks. The two portfolios also carry notable energy, financial, and healthcare exposure, so commodity prices, credit conditions, and pharmaceutical earnings cycles all influence fund performance. RDIV's heavier financials and energy tilt makes it more sensitive to rate and oil price swings, while SCHD's staples and healthcare emphasis gives it a more defensive character. Regulatory and policy developments affecting banks, energy producers, and drugmakers remain key swing factors for both strategies in recent market cycles.
Over recent market cycles, SCHD has generally delivered steadier relative positioning thanks to its quality filters and lower volatility, while RDIV has shown sharper swings tied to value and cyclical rotations. RDIV's concentrated, yield-first approach can outperform during strong value or energy rallies, but its higher expense ratio and single-stock concentration have weighed on longer-horizon risk-adjusted returns. SCHD's diversified, lower-cost structure and emphasis on dividend growth have supported more consistent compounding, albeit with a slightly lower headline yield. Investors weighing fund performance should note that RDIV offers a higher distribution yield but at the cost of greater cyclicality, while SCHD prioritizes dividend durability and total-return resilience across economic conditions.
In my own workflow, Tickeron’s AI Screener has become a useful way to quickly compare dividend ETFs like these on fundamentals, holdings overlap, and risk metrics. It surfaces patterns across thousands of names without requiring hours of manual data pulls, helping me stay focused on the structural differences that matter most for long-term allocation decisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day RSI Oscillator for SCHD moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 instances where the indicator moved out of the overbought zone. In 34 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a move down at 79%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 64 cases where SCHD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 75%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SCHD as a result. In 61 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for SCHD turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 33 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
SCHD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
SCHD moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SCHD crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 84%.
Following a +1.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHD advanced for three days, in 265 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 282 of 364 cases where SCHD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows